이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

KDTV001 Injection in Patients With Human Papillomavirus (HPV) Types 16, and/or 18, and/or 52 Associated Cervical High-Grade Squamous Intraepithelial Lesion .

2026년 11월 13일 업데이트: Wuhan KadGeno Biotechnology Co., Ltd

Phase 1/2, Multi-center, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of KDTV001 Injection in Patients With Human Papillomavirus (HPV) Types 16, and/or 18, and/or 52 Associated Cervical High-Grade Squamous Intraepithelial Lesion .

KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.

This is a Phase I, multicenter, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of KDTV001 Injection in participants with HPV types 16, and/or 18, and/or 52-associated cervical HSIL.

The study consists of three parts: dose escalation, an immunogenicity expansion cohort (Phase 1), and a dose expansion phase (Phase 2). In Phase 1a, 3+3 dose escalation of KDTV001 Injection will be conducted separately for IM and IC administration, with two ascending dose levels evaluated for each route. During the dose-escalation phase, if a dose cohort is assessed as safe by SRC, an immunogenicity expansion of 10-20 participants may be conducted. Based on Phase 1 safety and immunogenicity data, 1-2 dose levels will be selected for Phase 2 dose expansion for both IC and IM. In the Phase 2 dose-expansion phase, each dose cohort will enroll 30-50 participants. Both phases will consist of a screening period, a treatment and safety follow-up period, an end of study visit (EOS) and a long-term follow-up period.

연구 개요

연구 유형

중재적

등록 (추정된)

304

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Yanyan Zhang, MMed
  • 전화번호: +8618607163222
  • 이메일: Linda@whkdws.com

연구 장소

    • Hubei
      • Wuhan, Hubei, 중국
        • 모병
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • 수석 연구원:
          • Peng Wu, Prof
      • Wuhan, Hubei, 중국
        • 모병
        • TongJi Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • 연락하다:
          • Nan Yu, Prof
        • 수석 연구원:
          • Nan Yu, Prof
        • 수석 연구원:
          • Gang Chen, Prof

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

  • Cervical HSIL (defined as CIN 2 or 3), with the histological diagnosis confirmed by central pathology review within 12 weeks before the first study dose. Note: CIN 3 patients for whom immediate lesion removal is recommended by a clinician will not be enrolled in this study.
  • Confirmed cervical infection with HPV types 16, and/or 18, and/or 52 at screening by Central Lab. If there are other high-risk types of HPV infection, the investigator should assess based on the participant's infection history to exclude cases where such non-target types are persistent infections and the primary causes of disease.
  • All participants must have lesions of adequate size to ensure that a visible lesion remains after the screening biopsy.
  • Participants must have satisfactory colposcopy at screening, defined as full visualization of entire lesion and the squamo-columnar junction (Type I or II transformation zone).
  • Female participants aged ≥ 18 years.
  • No significant impairment of major organ functions, including but not limited to hematopoietic, cardiac, pulmonary, hepatic, and renal functions.
  • Female participants must meet one of the following criteria with respect their reproductive capacity:

a Post-menopausal as defined by spontaneous amenorrhea for more than 12 months; b Surgically sterile due to absence of ovaries or due to a bilateral tubal ligation/occlusion performed more than 12 months prior to screening; c Women of Child Bearing Potential (WOCBP) must have a negative serum pregnancy test during the screening period; participants must agree to use reliable contraceptive methods (barrier methods or abstinence) with their partners during the study and for at least 12 months after the last dose of investigational product.

- Be willing to participate in this study and provide a signed informed consent form prior to participating in the trial.

Exclusion Criteria:

  • Cervical adenocarcinoma in situ (AIS), atypical endometrial or glandular cells, or histopathological evidence of invasive cervical carcinoma on cervical biopsy within 12 weeks prior to the first study dose.

  • Have received pelvic radiotherapy within the past five years.

  • Have any active infection requiring systemic anti-infective treatment (routine prophylactic anti-infective treatment per the clinical trial institution is allowed) or an unexplained fever >38.5°C during the screening period.

  • Have more than three episodes of abnormal uterine bleeding within the recent three months.

  • Have a history of receiving adenovirus-based therapies within 6 months.

  • Participants with symptomatic vaginitis, including but not limited to bacterial, fungal, or trichomonal vaginitis. Participants may be eligible for enrollment after satisfactory treatment.

  • Participants who are pregnant, lactating, or unwilling to use protocol-defined contraception at any time during the study;

  • History of other organ systems malignancies within the past five years, which in the investigator's judgment may interfere with study conduct or require systemic anticancer therapy during the study.

  • Poorly controlled diabetes (defined as fasting blood glucose ≥ 10 mmol/L) despite medication at screening.

  • Major surgery within 4 weeks prior to the first dose or anticipated during the study (excluding diagnostic procedures). Participants must have fully recovered from the toxicities and/or complications of the prior major surgery if conducted more than 4 weeks prior to the first study dose.

  • Participants with hereditary bleeding diathesis or coagulopathy, history of thrombosis or hemorrhage, or requirement for chronic anticoagulant therapy.

  • Have a history of severe cardiovascular or cerebrovascular diseases, including but not limited to:

    1. Severe cardiac conduction abnormalities requiring clinical intervention (e.g. ventricular arrhythmias requiring treatment, second- or third-degree atrioventricular block).
    2. QTcF interval ≥ 460 ms on resting 12-lead ECG.
    3. Acute coronary syndrome, congestive heart failure, aortic dissection, cerebrovascular accident, or other Grade 3 or higher cardiovascular events occurring within six months prior to the first study dose.
    4. New York Heart Association (NYHA) functional classification ≥ Class II OR left ventricular ejection fraction (LVEF) <50%, OR other investigator-assessed high-risk structural heart diseases.
    5. Clinically uncontrolled hypertension.
  • Participants with autoimmune disorders or immunodeficiency conditions, or who have received allogeneic hematopoietic stem cell transplantation, or solid organ transplantation.

  • Asplenia, functional asplenia, or any condition resulting in absence or removal of the spleen.

  • Have any of the following serum virology findings:

    1. Positive HIV antibody test; OR

    2. Positive Treponema pallidum antibody; OR

    3. Active hepatitis B infection defined as:

      HBsAg positive AND HBV-DNA >500 IU/mL or above institutional detection limit if higher than standard threshold (only when the lower limit of detection threshold of the clinical trial institution is higher than 500 IU/mL)

    4. Active hepatitis C infection defined as: Anti-HCV positive AND HCV-RNA above institutional detection limit Note: Individuals receiving prophylactic antiviral therapies other than interferon are allowed to be enrolled.

  • Have uncontrolled seizures, central nervous system disorders, or psychiatric conditions resulting in loss of cognitive capacity.

  • Have a history within the past year of, or are currently experiencing, any other clinically significant uncontrolled medical conditions, including but not limited to cardiac, hepatic, pulmonary, renal, gastrointestinal, neurological, psychiatric, metabolic disorders.

  • Have received any blood products within three months prior to enrollment.

  • Require concomitant use of antiviral therapy OR have received antiviral medications within two weeks prior to the first administration of the study drug.

  • Have received any vaccination within four weeks prior to enrollment.

  • History of previous therapeutic HPV vaccination (individuals who have been immunized with licensed prophylactic HPV vaccines are not excluded).

  • Tattoos, scars, or active dermatologic lesions or rashes at the injection site that interfere with local safety assessments.

  • Currently receiving OR have received following doses of systemic corticosteroid therapy prior to the first administration of the investigational product:

    1. Long-term corticosteroid therapy: > 10 mg/day prednisone or equivalent within 30 days prior to the first study dose;
    2. Short-term corticosteroid therapy: ≥ 1 mg/kg/day prednisone or equivalent for ≥ 2 courses, each lasting >3 days, within 30 days prior to the first study dose.

Note: Topical, ocular, intra-articular, nasal, or inhaled corticosteroids are permitted.

  • Have a history of severe allergies or known allergic constitution.
  • Other conditions deemed unsuitable for study enrollment by the investigator.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Cohort A Dose Level 1

KDTV001:1 × 10^11 VP, IM, W0, W4, W12

KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.

실험적: Cohort A Dose Level 2

KDTV001: 3 × 10^11 VP, IM, W0, W4, W12

KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.

실험적: Cohort B Dose Level 1

KDTV001: 1 × 10^10 VP, IC, W0, W4, W12

KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.

실험적: Cohort B Dose Level 2

KDTV001: 3 × 10^10 VP, IC, W0, W4, W12

KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Phase 1: Incidence of Any Adverse Events (AEs), Treatment related AEs (TRAEs) and Serious Adverse Events (SAEs) Following Investigational Treatment for the Duration of the Study
기간: From enrollment to 2 years after the first dose.

Percentage of participants with AE/TRAE/SAE in FAS population

From enrollment to 2 years after the first dose.
Phase 2: Percentage of Participants With No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and HPV-18 and HPV-52 in Cervical Samples
기간: From enrollment to 36 weeks after the first dose.

Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL, no evidence of HPV-16 and HPV-18 and HPV-52 at the Week 36 time frame, and participants in which excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or low-grade intraepithelial lesion (LSIL). HPV testing will be performed using the cobas® assay and a second assay kit manufactured in China to identify HPV 52.

From enrollment to 36 weeks after the first dose.

2차 결과 측정

결과 측정
측정값 설명
기간
Phase 1: HPV clearance rates after dosing;
기간: From enrollment to 104 weeks after the first dose.

Incidence of Participants with no evidence of HPV-16 and HPV-18 and HPV-52 at Week 12, 24, and 36, and Week 52, 78, and 104 if the participants do not have excisional treatment. HPV testing will be performed using the cobas® assay and a second assay kit manufactured in China to identify HPV 52.

From enrollment to 104 weeks after the first dose.
Phase 2: The immunogenicity of KDTV001 injection;
기간: From enrollment to 52 weeks after the first dose.

Immunogenicity within 52 weeks after the first dose: cellular immune responses against E6/E7 of HPV16/18/52, including enzyme-linked immunospot (ELISPOT) assay and flow cytometry, etc.

From enrollment to 52 weeks after the first dose.
Companion biomarkers of KDTV001
기간: From enrollment to 52 weeks after the first dose.
  • HPV integration;
  • Patient HLA typing;
  • p16, HPV E6/E7 and Ki67 gene expression analysis as well as immune infiltration analysis, etc. of cervical tissues;
  • Cervical gene methylation level;
  • Cell-free Human Papillomavirus DNA (cfDNA-HPV), peripheral blood immune cell subsets, and related antibody production (e.g. peripheral blood antibodies to HPV16/18/52 E6/E7 and viral vector (Ad5)).
From enrollment to 52 weeks after the first dose.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 1월 6일

기본 완료 (추정된)

2027년 11월 30일

연구 완료 (추정된)

2029년 1월 30일

연구 등록 날짜

최초 제출

2026년 11월 4일

QC 기준을 충족하는 최초 제출

2026년 11월 13일

처음 게시됨 (실제)

2026년 11월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 19일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 13일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다